“Building on the promising preclinical results with CLR 125, we have submitted a Phase 1b dose-finding study protocol to the FDA for the treatment of triple-negative breast cancer, including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback